Abstract:

Alcohol dependence is a major cause of morbidity and mortality in the USA and throughout the world. Over the last 10 years there has been an intense interest in developing pharmacotherapies that address the neurochemistry of alcohol dependence. Using a novel pharmacological approach to treating alcohol dependence, topiramate (Topamax^®, Ortho–McNeil Pharmaceutical) has recently been shown to improve the drinking outcomes of alcohol-dependent individuals. This drug profile highlights the scientific concepts and clinical evidence in the development of topiramate for treating alcohol dependence.

Keywords: alcohol dependence; anticonvulsant; craving; pharmacotherapy; topiramate

Document Type: Drug Evaluation

DOI: 10.1586/14737175.4.5.751